Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL10609612 | 1.00 | KDM4E (0.52) | KDM4EBBOX1LMNAAPOBEC3AAPOBEC3G | |
| Iodide SCHEMBL902544 | 0.97 | BBOX1 (0.50) | KDM4EBBOX1LMNAAPOBEC3AAPOBEC3G | |
| SCHEMBL320814 | 0.97 | BBOX1 (0.50) | KDM4EBBOX1LMNAAPOBEC3AAPOBEC3G | |
| SCHEMBL205619 | 0.97 | BBOX1 (0.50) | KDM4EBBOX1LMNAAPOBEC3AAPOBEC3G | |
| Hydrogen Sulfide SCHEMBL16733010 | 0.95 | BBOX1 (0.48) | KDM4EBBOX1LMNAAPOBEC3AAPOBEC3G | |
| Bromide SCHEMBL8512450 | 0.95 | BBOX1 (0.48) | KDM4EBBOX1LMNAAPOBEC3AAPOBEC3G | |
| Fluoride SCHEMBL19179757 | 0.95 | BBOX1 (0.48) | KDM4EBBOX1LMNAAPOBEC3AAPOBEC3G | |
| Hydrochloric Acid SCHEMBL11371713 | 0.95 | BBOX1 (0.52) | KDM4EBBOX1LMNAAPOBEC3AAPOBEC3G | |
| Water SCHEMBL15375324 | 0.95 | BBOX1 (0.48) | KDM4EBBOX1LMNAAPOBEC3AAPOBEC3G | |
| Iodide SCHEMBL8953760 | 0.95 | BBOX1 (0.48) | KDM4EBBOX1LMNAAPOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162435-B1 | Ionic liquids as electrolytes | INVISTA TECH SARL (CH) | 2013-09-04 | — | — | EP | disclosed |
| US-8345407-B2 | Low viscosity ionic liquids | INVISTA NORTH AMERICA S.A R.L. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2534134-A1 | LOW VISCOSITY IONIC LIQUIDS | Invista Technologies S.à.r.l. (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-20120190844-A1 | IONIC LIQUIDS | INVISTA NORTH AMERICA S.A R.L. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120050945-A1 | LOW VISCOSITY IONIC LIQUIDS | INVISTA NORTH AMERICA S.A R.L. (US) | 2012-03-01 | — | — | US | disclosed |
| US-8088917-B2 | Ionic liquids | INVISTA NORTH AMERICA S.A R.L. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011100232-A1 | LOW VISCOSITY IONIC LIQUIDS | INVISTA TECHNOLOGIES S.A R.L. (CH) | 2011-08-18 | — | — | WO | disclosed |
| EP-2162435-A1 | IONIC LIQUIDS AS ELECTROLYTES | Invista Technologies S.A.R.L. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008150842-A1 | IONIC LIQUIDS AS ELECTROLYTES | INVISTA TECHNOLOGIES S.A.R.L. (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080296531-A1 | IONIC LIQUIDS | INVISTA NORTH AMERICA S.A R.L. (US) | 2008-12-04 | — | — | US | disclosed |
| US-5521261-A | PERHYDROAZEPINIUM OR OCTAHYDROAZOCINIUM SALT FOR CHAIN EXTENSION | CIBA-GEIGY CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190844-A1 | IONIC LIQUIDS | INF2, H1-2, H1-0 | CHRM1 88/4885CHRM3 400/4885KDM4E 4527/4885 |
| US-20120050945-A1 | LOW VISCOSITY IONIC LIQUIDS | H1-3, H1-0, H1-2 | CHRM1 30/4885CHRM3 40/4885KDM4E 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.